Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
Pazopanib is a tyrosine kinase inhibitor indicated for the treatment of renal cell carcinoma and soft tissue sarcoma. Despite the high inter-patient variability in pharmacokinetic exposure, pazopanib is administered at a fixed dose of 800 mg once daily (QD). Pharmacokinetic exposure is linked to both efficacy and toxicity. In this case report, we illustrate the value of therapeutic drug monitoring by describing two patients with adequate pazopanib trough concentrations (Cmin) at an eight times lower than standard dose.
Patient A is a 69-year-old woman with metastatic leiomyosarcoma who had significant toxicities and a high Cmin on the standard dose. While dose reductions to 200 mg QD and later 200 mg every other day were made, pazopanib Cmin remained above the efficacy threshold. Patient B is a 50-year-old male with metastatic angiosarcoma and a history of Gilbert syndrome. Pazopanib treatment was initiated at the standard dose of 800 mg QD, but was reduced to 200 mg QD 1-week-on - 1-week-off due to total bilirubin elevation. Pazopanib Cmin was adequate in this patient as well.
It could be valuable to measure pazopanib levels in case of dose reductions due to toxicity, as exposure could still be adequate at considerably lower than standard doses.
KeywordsTherapeutic drug monitoring Pazopanib Toxicity
Minimum blood concentration
Every other day
Summary of product characteristics
Therapeutic drug monitoring
Uridine diphosphoglucuronate glucuronosyltransferase 1A1
Pazopanib is a tyrosine kinase inhibitor mainly targeting the vascular endothelial growth factor receptor and is indicated for the treatment of advanced renal cell carcinoma and soft tissue sarcoma . Despite the high inter-patient variability in exposure (40–70%), pazopanib is administered at a fixed oral dose of 800 mg once daily (QD) [1, 2]. Suttle et al reported a clear exposure-response relationship, with patients with a pazopanib trough concentration (Cmin) above 20.5 mg/L having a significantly longer progression-free survival (PFS). Also, an exposure-toxicity relationship has been demonstrated, with an increasing incidence of toxicities such as hypertension, diarrhea, elevated alanine aminotransferase levels, stomatitis and hand-foot syndrome with increasing pazopanib plasma concentrations . It has been shown that patients are unlikely to tolerate Cmin ≥ 50 mg/L for a prolonged period of time . In this case report, we illustrate the value of therapeutic drug monitoring (TDM) for pazopanib by describing two patients with pazopanib Cmin above the efficacy threshold of 20.5 mg/L at an eight times lower than standard dose.
The second case is a 50-year-old male with metastatic angiosarcoma and a history of Gilbert syndrome, previously treated with 6 cycles of doxorubicin in combination with ifosfamide. Pazopanib treatment was started at the standard dose of 800 mg QD. Shortly hereafter, total bilirubin increased to twice the upper limit of normal with only minimal elevation of direct bilirubin, after which pazopanib was halted. Upon normalization of bilirubin, pazopanib treatment was resumed at a reduced dose of 400 mg QD and later 200 mg QD 1-week-on – 1-week-off. At the end of the on-treatment week pazopanib Cmin was 29.9 mg/L (Fig. 1b). The patient is still on treatment now, nine months after pazopanib initiation, with a partial remission.
Discussion and conclusion
It is remarkable that even these unusually low doses of pazopanib lead to an adequate exposure, defined by Cmin ≥ 20.5 mg/L.  In the absence of TDM, when doses would be reduced according to the Summary of Product Characteristics (SPC), treatment would probably have been discontinued in these patients, as the SPC considers the exposure at 200 mg QD as markedly reduced and insufficient to obtain a clinically relevant effect . However, we observed an adequate Cmin at considerably lower than standard doses and treatment could have been continued for 14 and 9 months (ongoing response), respectively. This is a relative long duration of response taking into account the median PFS of 4.6 months for sarcoma patients found in the phase 3 trial . Although the efficacy threshold of Cmin ≥ 20.5 mg/L has been established in patients with renal cell carcinoma , a similar trend has been demonstrated in sarcoma patients .
Gilbert’s syndrome, uridine diphosphoglucuronate glucuronosyltransferase 1A1 (UGT1A1) polymorphism, has been associated with pazopanib-induced hyperbilirubinemia, which was probably the case in the second patient . Given the benign etiology of this condition, continuing pazopanib treatment was possible, although in reduced dose.
With regard to obtaining the most adequate exposure, the dosing regimen of 200 mg every other day is most rational, as with the 200 mg 1-week-on, 1-week-off regimen patients will probably not have an adequate exposure in the off-treatment week. Unfortunately, we do not have any trough concentrations in the off-treatment week of patient B available.
As we illustrated with these two cases, it could be valuable to measure pazopanib levels in case of dose reductions due to toxicity, as Cmin could still be above the efficacy threshold at considerably lower than standard doses.
No funding was received for this research.
Availability of data and materials
Additional information is available from the corresponding author upon reasonable request.
Conception and design of this case series, analysis and interpretation of data were performed by SG, AH and NS; SG wrote the manuscript; SG and DK collected the data; DK and NS treated the patients; DK, NS and AH critically reviewed the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
Written informed consent for publication for publication of their clinical details and/or clinical images was obtained from the patient/relative of the patient. A copy of the consent form is available for review by the Editor of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Summary of Product Characteristics of pazopanib. Available from: http://www.ema.europa.eu/docs/nl_NL/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdfGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.